Radioiodinated 2-hydroxy-3-(4-iodophenyl)-1-(4-phenylpiperidinyl)propane, 5 (4-HIPP), was synthesized and evaluated as a simple vesamicol-like radiotracer for mapping cholinergic pathways in the brain. Both enantiomers of 5 exhibit significant accumulation (approx. 2% of injected dose) and prolonged retention (t1/2 greater than 3 h) within the rat brain. The accumulation of radioiodinated 5 in the rat brain was reduced by up to 70% in the presence of vesamicol and its analogs. The levorotary isomer (-)-4-[123I]HIPP exhibits significant accumulation in the monkey brain, with a half-life of about 9 h. Radioiodinated 5 may therefore be a useful tool for studying cholinergic pathways in the brain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0883-2897(92)90119-j | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Investigation of Somatostatin Receptors as a Potential Target in Breast Phyllodes Tumours.
Diagnostics (Basel)
December 2024
Department of Surgery, School of Medicine, Acıbadem Mehmet Ali Aydınlar University, 34752 Istanbul, Turkey.
Background: Somatostatin receptors (SSTRs) are expressed in most neuroendocrine neoplasms, particularly in gastroenteropancreatic neuroendocrine tumours, and have been utilised as diagnostic markers and therapeutic targets. The radioiodinated somatostatin analogue 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid- Tyr3-octreotate (DOTATATE) has been employed for SSTR targeting for either diagnostic or therapeutic purposes depending on the labelling with Gallium or Lutetium, respectively. SSTR expression is reported in a subset of breast adenocarcinoma and breast neuroendocrine carcinomas; however, minimal knowledge exists regarding their expression in fibroepithelial (biphasic) breast lesions such as fibroadenoma and phyllodes tumours.
View Article and Find Full Text PDFIn Vivo Stability Improvement of Astatobenzene Derivatives by Introducing Neighboring Substituents.
J Med Chem
January 2025
Graduate School of Medical Sciences, Kanazawa University, Kakuma-Machi, Kanazawa, Ishikawa 920-1192, Japan.
At is a promising radiohalogen for targeted α therapy. However, some astatinated compounds undergo deastatination in vivo, leading to unintended astatine accumulation in nontarget tissues. Recently, a group reported that the in vivo stability of an astato group on an alkyl group could be improved by placing specific substituents around the astato group.
View Article and Find Full Text PDFDevelopment of a Novel Prosthetic Click-Linker for Radioiodination of Antibody-Based Radiopharmaceuticals with High Stability and Specificity.
Mol Pharm
January 2025
Division of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.
Article Synopsis
- Radioiodine is used in nuclear medicine for diagnosing and treating diseases, primarily through two methods of radioiodination: direct and indirect.
- The newly developed compound 3-[I]IBTTT offers a high radiochemical yield and purity while simplifying purification processes, overcoming issues present in traditional methods.
- This compound demonstrated effective HER2-specific binding in tumor imaging with minimal thyroid uptake, making it a promising option for targeting HER2-positive cancers.
Development of a novel radioiodinated compound for amyloid and tau deposition imaging in Alzheimer's disease and tauopathy mouse models.
Neuroimage
December 2024
Department of Radiopharmacy and Molecular Imaging, Minhang Hospital & School of Pharmacy, Fudan University, Shanghai, China; Department of Functional Brain Imaging Research, China; Department of Clinical and Experimental Neuroimaging, Centre for Development of Advanced Medicine for Dementia, National Centre for Geriatrics and Gerontology, Obu, Japan; Key Laboratory of Smart Drug Delivery, Fudan University, Ministry of Education, Shanghai, China; Institute for Small-Molecule Drug Discovery & Development, Quzhou Fudan Institute, Quzhou, China. Electronic address:
Article Synopsis
- - The study focused on a new compound called AD-DRK (I-AD-DRK) that can non-invasively identify amyloid-β and tau deposits in the brain, which are critical for diagnosing Alzheimer's disease and related disorders.
- - Researchers conducted tests using this compound in both postmortem human brains and mouse models with amyloid and tau accumulation, demonstrating its effective binding and visualization capabilities in the brain regions associated with these proteins.
- - The results showed that I-AD-DRK has strong potential as a SPECT imaging agent, offering high-contrast imaging of amyloid and tau, which could significantly help in early diagnosis and treatment of Alzheimer's disease and other tauopathies.
Radioiodinated Nanobody immunoPET probe for in vivo detection of CD147 in pan-cancer.
Eur J Nucl Med Mol Imaging
November 2024
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Background: To develop the extracellular matrix metalloproteinase inducer (CD147)-targeting therapeutic strategies, accurate detection of CD147 expression in tumors is crucial. Owing to their relatively low molecular weights and high affinities, nanobodies (Nbs) may be powerful candidates for cancer diagnosis and therapy. In this study, we developed a novel CD147-targeted nanobody radiotracer, [I]I-NB147, which provides guidance for the noninvasive detection of CD147-overexpressing cancers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!